﻿<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.google.com/schemas/sitemap/0.84" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.google.com/schemas/sitemap/0.84 http://www.google.com/schemas/sitemap/0.84/sitemap.xsd">
  <url>
    <loc>http://fdadrugs.legalview.com/legal-issue/activase/</loc>
    <lastmod>2012-02-23</lastmod>
  </url>
  <url>
    <loc>http://fdadrugs.legalview.com/legal-issue/activase/fda-alerts/</loc>
    <lastmod>2012-02-23</lastmod>
  </url>
  <url>
    <loc>http://fdadrugs.legalview.com/legal-issue/activase/fda-alerts/news-along-the-pike-august-2004-issue/447654/</loc>
    <lastmod>2012-02-23</lastmod>
  </url>
  <url>
    <loc>http://fdadrugs.legalview.com/legal-issue/activase/fda-alerts/tnk-tpa-tnk-tenecteplase-50-mg-product-approval-information-licensing/447655/</loc>
    <lastmod>2012-02-23</lastmod>
  </url>
  <url>
    <loc>http://fdadrugs.legalview.com/legal-issue/activase/fda-alerts/cber-alteplase-cathflo-activase-genentech-incorporated/447656/</loc>
    <lastmod>2012-02-23</lastmod>
  </url>
  <url>
    <loc>http://fdadrugs.legalview.com/legal-issue/activase/fda-alerts/cber-alteplase-activase-genentech-incorporated/447657/</loc>
    <lastmod>2012-02-23</lastmod>
  </url>
  <url>
    <loc>http://fdadrugs.legalview.com/legal-issue/activase/fda-alerts/difficulties-in-obtaining-sufficient-amounts-of-urokinase-abbokinase/447658/</loc>
    <lastmod>2012-02-23</lastmod>
  </url>
  <url>
    <loc>http://fdadrugs.legalview.com/legal-issue/activase/fda-alerts/alteplase-product-approval-information-licensing-action/447659/</loc>
    <lastmod>2012-02-23</lastmod>
  </url>
  <url>
    <loc>http://fdadrugs.legalview.com/legal-issue/activase/fda-alerts/alteplase-product-approval-information-licensing-action/447660/</loc>
    <lastmod>2012-02-23</lastmod>
  </url>
  <url>
    <loc>http://fdadrugs.legalview.com/legal-issue/activase/fda-alerts/cber-approval-letter-supplement-for-alteplase-to-include-an-indication/447661/</loc>
    <lastmod>2012-02-23</lastmod>
  </url>
  <url>
    <loc>http://fdadrugs.legalview.com/legal-issue/activase/fda-alerts/violative-advertising-and-promotional-labeling-letter-reteplase-retava/447662/</loc>
    <lastmod>2012-02-23</lastmod>
  </url>
  <url>
    <loc>http://fdadrugs.legalview.com/legal-issue/activase/news-articles/</loc>
    <lastmod>2012-02-23</lastmod>
  </url>
  <url>
    <loc>http://fdadrugs.legalview.com/legal-issue/activase/news-articles/sitemap.xml</loc>
    <lastmod>2012-02-23</lastmod>
  </url>
  <url>
    <loc>http://fdadrugs.legalview.com/legal-issue/activase/msn/</loc>
    <lastmod>2012-02-23</lastmod>
  </url>
  <url>
    <loc>http://fdadrugs.legalview.com/legal-issue/activase/msn/sitemap.xml</loc>
    <lastmod>2012-02-23</lastmod>
  </url>
  <url>
    <loc>http://fdadrugs.legalview.com/legal-issue/activase/thank-you.aspx</loc>
    <lastmod>2012-02-23</lastmod>
  </url>
  <url>
    <loc>http://fdadrugs.legalview.com/legal-issue/activase/disclaimer.aspx</loc>
    <lastmod>2012-02-23</lastmod>
  </url>
  <url>
    <loc>http://fdadrugs.legalview.com/legal-issue/activase/ContactUs.aspx</loc>
    <lastmod>2012-02-23</lastmod>
  </url>
  <url>
    <loc>http://fdadrugs.legalview.com/legal-issue/activase/local/</loc>
    <lastmod>2012-02-23</lastmod>
  </url>
  <url>
    <loc>http://fdadrugs.legalview.com/legal-issue/activase/local/sitemap.xml</loc>
    <lastmod>2012-02-23</lastmod>
  </url>
</urlset>
